

August 20, 2026

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Press Release

Please find enclosed herewith the Press Release titled “*Mankind Pharma Enters into Exclusive In-Licensing Agreement for Insulin Degludec and Insulin Degludec + Aspart Combination for India*”, which is self-explanatory and same has been released to the press today.

The above-mentioned Press Release is also being uploaded on the website of the company i.e. www.mankindpharma.com.

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Hitesh Kumar Jain
Company Secretary &
Compliance Officer

Encl.: A/a

Mankind Pharma Enters into Exclusive In-Licensing Agreement for Insulin Degludec and Insulin Degludec + Aspart Combination for India

Partnership further strengthens Mankind Pharma's growing presence in the diabetes segment and expands its injectable diabetes portfolio

New Delhi, 20th August 2026 : Mankind Pharma Limited, one of India's leading pharmaceutical companies, has entered into an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd., China, for the commercialisation of two insulin analogues, Insulin Degludec and Insulin Degludec + Aspart Combination, in India.

The partnership marks another significant step in Mankind Pharma's strategy to strengthen its presence in diabetes care and broaden its portfolio of advanced injectable therapies. The addition of these products will further enhance, Mankind Pharma's position in the injectable diabetes segment, contributing to a more comprehensive portfolio and reinforcing its commitment to addressing the evolving needs of patients.

The latest partnership further reinforces the company's commitment to expanding its diabetes portfolio and bringing a broader range of treatment options to patients in India.

Commenting on the partnership, **Atish Majumdar, Senior President – Sales and Marketing, Mankind Pharma Ltd.**, said, *"China is rapidly emerging as a hub for innovative biopharmaceutical assets. Building on our partnerships for Insulin Aspart and Insulin Degludec, we remain focused on expanding our in-licensing pipeline from China. This partnership reinforces our commitment to expanding access to advanced therapies for patients in India while further strengthening our presence in the injectable diabetes segment."*

The partnership with Chongqing Chenan Biopharmaceutical is also aligned with Mankind Pharma's broader strategy of leveraging global innovation through strategic partnerships and in-licensing opportunities. China's rapidly developing biopharmaceutical ecosystem presents opportunities for Indian pharmaceutical companies to access differentiated and innovative assets that can complement their existing portfolios.

About Mankind Pharma Limited

Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynaecology, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. Following the acquisition of BSV, Mankind Pharma has further

strengthened its leadership in the domestic women's health segment. Mankind's distribution network includes a robust field force of 18,500+ professionals, and a reach extending to over five lakh doctors across urban and rural markets. The company has 32 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 7 dedicated R&D facilities backed by more than 740 scientists.

For more information, visit www.mankindpharma.com *or contact:*

Natasha Raj - 9205057627 - natasha.raj@mankindpharma.com

Apoorva Sharma - 9999739452 - apoorva.sharma@adfactorspr.com